Riskpilot← Back to searchSign inGet full accessAlere Toxicology AB
ABDissolvedOrg 5562626787Wholesale of other machinery and equipment · NACE 4669Est. 19857 employees
Revenue 2019
SEK 33,2M
-14% vs 2018
EBITDA margin
3.2%
+257% vs 2018
Equity ratio
72.7%
Financial strength
Net profit 2019
SEK 2,4M
+69% vs 2018
| Revenue | SEK 33,2M | -14% |
| EBITDA | SEK 1,1M | +257% |
| Net profit | SEK 2,4M | +69% |
| Total assets | SEK 55,9M | -2% |
| Equity | SEK 40,6M | +6% |
| Employees | 7 | — |
Legal name
Alere Toxicology AB
Org number
5562626787
Legal form
Aktiebolag
NACE code
4669 · Wholesale of other machinery and equipment
Founded
16 juli 1985
Share capital
SEK 0
Employees
7 (FTE)
VAT registered
No
Audit selected
No
Last report
2019-12-31
Financial year
January – December
Company purpose
Bolaget skall bedriva marknadsföring av medicinska produkter, av datorer, äga och förvalta fast egendom, ävensom lös egendom, huvudsakligen aktier och metaller samt idka därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|
| Revenue | 37 809 | 40 716 | 38 702 | 33 176 |
| Staff expenses | — | — | — | — |
| EBITDA | −61 | 2 100 | −686 | 1 077 |
| Depreciation & amort. | −793 | −11 | −8 | −26 |
| EBIT | −854 | 2 089 | −694 | 1 051 |
| Net financials | 1 751 | 2 710 | 1 015 | 878 |
| Profit before tax | 462 | 3 578 | 1 865 | 3 128 |
| Tax | −287 | −805 | −433 | −707 |
| Net profit | 175 | 2 773 | 1 432 | 2 421 |
| Item | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|
| Total assets | 69 612 | 67 081 | 56 938 | 55 890 |
| Equity | 34 001 | 36 774 | 38 206 | 40 627 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 23 576 | 17 052 | 7 021 | 4 752 |
| Total debt | 23 576 | 17 052 | 7 021 | 4 752 |
EBITDA margin
3.2%
This company
15.8%
Market median
-80% vs market
20162019
Equity ratio
72.7%
This company
38.2%
Market median
+90% vs market
20162019
Return on equity
6.0%
This company
18.4%
Market median
-67% vs market
20162019
Net profit margin
7.3%
This company
8.1%
Market median
-10% vs market
20162019
Asset turnover
0.59×
This company
1.12×
Market median
-47% vs market
20162019
Debt / equity
0.38×
This company
0.62×
Market median
+39% vs market
20162019
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
JA Chief Auditor | Chief Auditor | 2020 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Former (7) | ||
| Board of Directors | 2020 – 2020 | |
| Chairman | 2020 – 2020 | |
| Chairman | 2020 – 2021 | |
| Board of Directors | 2020 – 2021 | |
| Board of Directors | 2020 – 2020 | |
| Board of Directors | 2020 – 2021 | |
| Board of Directors | 2020 – 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Alere Toxicology AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| John Anders Liljenfeldt | Chief Auditor | 0 companies |
| Andreas Lennart Gottlieb Juhlin | Board of Directors | 0 companies |
| Tomas Dan-Ola Blomquist | Chairman | 0 companies |
| Erik Dahl Jensen | Chairman | 0 companies |
| Jennifer Caroline Deeley | Board of Directors | 0 companies |
| Petter Aspaas | Board of Directors | 0 companies |
| Linn Emily Areljung | Board of Directors | 0 companies |
| Eva Marie Elisabeth Drott | Board of Directors | 0 companies |